DVA Forensic analysis
Price Targets (12m)
Detailed research
PART 1: TRADING EXECUTION
Trading Setup & Entry Strategy
- >Entry Zone: $182.00 - $188.00. Current price of $194.61 is extended. I recommend waiting for a test of the previous breakout level near the 50-day SMA ($160.44 is too low; $185 is the immediate support floor).
- >Stop Loss: $174.00 (Hard Stop). Positioned below the recent consolidation base to avoid noise.
- >Position Sizing: 3% of portfolio. This is a momentum-driven trade in a high-RSI environment.
- >Take Profit: $210.00 (initial) and $219.00 (Bollinger Upper Band).
- >Risk/Reward: 1:2.4.
- >Max Hold Time: 10 Trading Days.
Executive Summary
DaVita (DVA) shows strong momentum with a 29.83% 20-day gain. Fundamentals are solid, with Q1 2026 Net Income of $197.53M vs. $162.91M YoY. Despite being slightly overbought (RSI 68.65), the trend remains firmly bullish, supported by active share buybacks and strong operational efficiency.
PART 2: DETAILED RESEARCH
Recent Material Events (8-K Analysis)
- >Feb 2026: Signed definitive agreement to acquire minority interest in Elara Caring for $200M, signaling growth in home health and hospice to diversify beyond dialysis.
- >Nov 2025: Refinancing and expansion of credit facilities, ensuring long-term liquidity and managing interest rate risk via interest rate caps.
Insider Trading
Recent activity indicates regular filings (May 18, 2026). While volume details were not parsed, the consistency suggests standard 10b5-1 selling or equity compensation settlement rather than aggressive dumping.
Financial Health
- >Revenue Quality: Strong. Dialysis patient service revenues grew to $3.27B from $3.10B YoY.
- >Debt/Liquidity: Total long-term debt is $10.51B. Coverage is managed via interest rate cap agreements (Notional coverage: $3.50B).
- >Efficiency: Operating income grew to $481.89M (Q1 2026) vs $438.94M (Q1 2025).
Technical Analysis & Trade Timing
- >Trend: BULLISH_UPTREND. Price is significantly above 50-day and 200-day SMAs.
- >Momentum: RSI at 68.65 indicates the stock is nearing overbought territory. The MACD histogram is positive (+1.89), suggesting continued momentum, but watch for a crossover if the price fails to hold $190.
- >Reconciliation: Fundamentals (EPS growth/buybacks) justify the premium, but technicals are extended. Avoid chasing the current price.
Short-Term Trading Strategy (2-5 Days)
- >Timeframe: Swing Trade (2–5 Days).
- >Scaling: Buy 1% at $188, add 2% at $182.
- >Exit: Take 50% profit at $205, balance at $215.
Thesis: DVA is executing a robust buyback program while growing into home-care markets. As long as the $180 support level holds, the path of least resistance is higher.
Investment Recommendation
RATING: BUY (ON PULLBACK). High conviction for momentum growth; wait for the RSI to cool before layering in.